TG Therapeutics Reports Interim Data From UNITY-NHL Phase 2b Trial On Umbralisib Monotherapy In Patients with Marginal Zone Lymphoma Showed Overall Response Rate Of 52%, Complete Response Of 19%, Was Well Tolerated